Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab maintenance after auto-HSCT in Hodgkin Lymphoma
NCT03436862Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- May 2018
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in Hodgkin lymphoma (HL), sponsored by SCRI Development Innovations. Started May 2018; status: completed.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT03436862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03436862.